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Abstract
Background: BRCA1 mutation carriers face a high lifetime risk of developing both breast and ovarian cancer.
Haploinsufficiency is thought to predispose these women to cancer by reducing the pool of available BRCA1
transcript and protein, thereby compromising BRCA1 function. Whether or not cancer-free BRCA1 mutation carriers
have lower messenger (m)RNA transcript levels in peripheral blood leukocytes has not been evaluated. The primary
aim of this study was to characterize an association between BRCA1 mutation status and BRCA1 mRNA leukocyte
expression levels among healthy women with a BRCA1 mutation.
Method: RNA was extracted from freshly isolated peripheral blood leukocytes of 58 cancer-free, female participants
(22 BRCA1 mutation carriers and 36 non-carriers). The expression levels of 236 cancer-associated genes, including
BRCA1, were quantified using the Human Cancer Reference gene panel from the Nanostring Technologies
nCounter Analysis System.
Results: Multivariate modeling demonstrated that carrying a BRCA1 mutation was the most significant predictor of
BRCA1 mRNA levels. BRCA1 mRNA levels were significantly lower in BRCA1 mutation carriers compared to non-
carriers (146.7 counts vs. 175.1 counts; P = 0.002). Samples with BRCA1 mutations within exon 11 had lower BRCA1
mRNA levels than samples with mutations within the 5′ and 3′ regions of the BRCA1 gene (122.1 counts vs. 138.9
and 168.6 counts, respectively; P = 0.003). Unsupervised hierarchical clustering of gene expression profiles from
freshly isolated blood leukocytes revealed that BRCA1 mutation carriers cluster more closely with other BRCA1
mutation carriers than with BRCA1 wild-type samples. Moreover, a set of 17 genes (including BRCA1) previously
shown to be involved in carcinogenesis, were differentially expressed between BRCA1 mutation carriers and
non-carriers.
Conclusion: Overall, these findings support the concept of BRCA1 haploinsufficiency wherein a specific mutation
results in dosage-dependent alteration of BRCA1 at the transcriptional level. This study is the first to show a
decrease in BRCA1 mRNA expression in freshly isolated blood leukocytes from healthy, unaffected BRCA1 mutation
carriers.
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Background
Women with a mutation in the breast cancer suscepti-
bility gene 1 (BRCA1) face a high lifetime risk of devel-
oping breast and ovarian cancer estimated to be as high
as 80 % and 40 %, respectively [1–4]. BRCA1 regulates
several key functions pertinent to cell survival, prolifera-
tion, and differentiation [5, 6]. In particular, BRCA1
helps maintain genomic stability by participating in the
cellular DNA damage response through homologous re-
combination (HR)-mediated repair of double-stranded
DNA breaks (DSBs) [7]. There is accumulating evidence
that BRCA1 haploinsufficiency is a driver of tumor pre-
disposing events in BRCA1 mutation carriers [8].
For haploinsufficiency to be an early driver of BRCA1-
associated cancer development, mutation-dependent re-
duction in BRCA1 expression levels should be associated
with a loss of function [8–10]. Most studies that have
characterized phenotypic alterations suggest that BRCA1
heterozygous cells have reduced functions in DNA dam-
age repair, hormonal regulation, cell fate changes, tran-
scriptional regulation and autophagy [11–21]; however,
little is known about whether the abrogated functions
observed in BRCA1 heterozygous cells are correlated
with changes in BRCA1 transcript or protein levels
[19, 22–24]. This is important in light of data sug-
gesting that the type and location of a mutation can
stratify cancer risk (i.e., breast vs. ovary), and the re-
sponse to treatment [25–29].
Regulation of BRCA1 gene expression is influenced by
genetic and epigenetic mechanisms, and environmental
factors such as genotoxic, hormonal, and metabolic
stressors [30]. Understanding the contribution of the mu-
tation status to basal expression levels of the BRCA1 gene
is a crucial step to delineating BRCA1 haploinsufficiency.
Previous studies using immortalized lymphoblastoid cell
lines have reported differential messenger RNA (mRNA)
or protein expression in BRCA1 mutation carriers com-
pared to non-carriers, suggesting a mutation-specific dos-
age effect [19, 24, 31]. In contrast, Feilotter et al. [18] did
not find BRCA1 to be among the set of 43 genes that can
predict BRCA1 mutation status by gene expression profil-
ing. However, differences in BRCA1 mRNA expression
may have been masked by the continuous proliferative
state of immortalized lymphoblastoid cell lines used in
these experiments [22, 32–37]. There are no studies, to
our knowledge, that have evaluated BRCA1 transcript
levels in freshly isolated blood leukocytes.
Notably, reduced BRCA1 protein expression in both
inherited and sporadic forms of breast and ovarian can-
cer has been associated with a significant reduction in
the levels of BRCA1 mRNA, thereby supporting the util-
ity of BRCA1 transcript levels as a surrogate marker of
BRCA1 function [38–40]. The overall goal of the current
study was to evaluate the relationship between BRCA1
mutation status (and mutation type) and mRNA expres-
sion among women with and without a BRCA1 muta-
tion, by studying freshly isolated blood leukocytes.
Methods
Study design and population
There were 58 women enrolled in the current study: 22
BRCA1 mutation carriers and 36 non-carriers. All women
were 18 years of age or older, none had a personal history
of cancer, and none were pregnant or breastfeeding. The
first group included women with a BRCA1 mutation,
identified from an existing database at the Familial Breast
Cancer Research Unit, Women’s College Research Insti-
tute (WCRI, Toronto, Canada) who were contacted by let-
ter. The second group included women from the general
population who were recruited using various methods
such as posters, newsletters or social media. A 30-minute
study appointment was then scheduled at the WCRI for
all the eligible participants. This research received ap-
proval from the Research Ethics Board at the Women’s
College Hospital (number 2012-0055-B). All women
provided informed consent to participate in the study
by signing the provided consent form.
Data and biological sample collection
Study participants completed a questionnaire, which col-
lected information on various exposures, including repro-
ductive and lifestyle factors, medical history, and family
history of cancer. Standardized procedures were used to
collect measurements of weight (kg) and height (m) to cal-
culate body mass index (BMI; kg/m2). A phlebotomist
drew blood into two labeled EDTA-containing tubes (ap-
proximately 8 mL) by venipuncture. The samples were
placed on ice and delivered immediately to the Women’s
College Hospital research laboratory for RNA extraction.
RNA isolation and quantification
RNA was isolated from one of the two EDTA tubes
using the LeukoLOCK Total RNA Isolation System
(Ambion, USA). This system is optimized for use with
human blood and offers the isolation of total RNA from
the leukocyte population [41]. In order to maximize
RNA isolation yield, all samples were stabilized with
RNALater® within 35 minutes of the blood draw. The
nucleic acid content was quantified using the Nanodrop
spectrophotometer (ThermoScientific). Total RNA qual-
ity and quantity was then determined using the Agilent
2100 Bioanalyzer (The Centre for Applied Genomics,
Toronto, Canada). The resulting extracted RNA was
stored at -80 °C until required for further analysis.
nCounter NanoString gene expression profiling
The nCounter Analysis System (NanoString Technologies)
was used to measure mRNA gene expression (expressed
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as counts) at the University Health Network (Toronto,
Canada) [42] using the Human Cancer Reference Kit con-
sisting of 236 cancer-related genes. Briefly, the nCounter
Analysis System probe library contains two sequence-
specific probes, the capture probe and the reporter probe,
for each gene of interest. Probe pairs are mixed with total
RNA in one hybridization reaction, and then the struc-
tures are imaged with the use of fluorescent microscopy.
Expression is measured by counting the number of unique
color tags within the gene-probe tripartite structures and
is reported as counts, a direct measure of the number of
RNA transcripts of each gene of interest.
Data acquisition and normalization was carried out
using the nSolver Analysis software version 2.0
(NanoString Technologies). Positive and negative controls
were used to check for background expression. Reference
housekeeping gene normalization was then performed to
adjust counts relative to probes that are not expected to
vary between samples or replicates, allowing meaningful
comparisons between samples. We chose the set of house-
keeping genes recommended by Nanostring, which com-
prised the following genes: CLTC (clathrin, heavy chain),
GAPDH (glyceraldehyde-3-phosphate dehydrogenase),
GUSB (glucuronidase, beta), HPRT1 (hypoxanthine phos-
phoribosyltransferase 1), TUBB (tubulin, beta class 1), and
PGK1 (phosphoglycerate kinase 1).
Statistical analysis
Student’s t test was used to compare continuous variables in
mutation carriers and non-carriers and the chi-square test
was used to test for differences in categorical variables. The
Shapiro-Wilk test was used to verify the normality of
BRCA1 mRNA expression. As expression of BRCA1 was
normally distributed (P= 0.26), the Pearson correlation coef-
ficient (ρ) was used to evaluate the correlation between
BRCA1 mRNA expression, BRCA1 mutation status and
various reproductive and lifestyle factors. Linear regression
was used to evaluate the relationship between BRCA1muta-
tion status and mRNA expression, adjusting for signifi-
cant predictors of BRCA1 mRNA levels including
parity (parous/nulliparous), breastfeeding (ever/never),
and menopausal status (premenopausal/postmenopausal).
A significance level of P <0.05 was used as the criterion
for including variables in the multivariate model.
We assigned the BRCA1 mutations into one of three mu-
tation clusters reported to be differentially associated with
the risk of breast vs. ovarian cancer: group 1 contained mu-
tations in exons 1–10; group 2 contained mutations in exon
11; and group 3 contained mutations in exons 12–22 [28].
One-way analysis of variance (ANOVA) was used to com-
pare mean BRCA1 expression levels between the three mu-
tation clusters.
Unsupervised hierarchical clustering was performed
using Pearson-centered correlation metric with centroid
linkage to categorize samples into homogenous groups
based on similar levels of gene expression. Heat maps
were generated using Java Treeview [43]. Student’s t test
was used to identify genes expressed differentially be-
tween BRCA1 mutation carriers and non-carriers by
testing for differences in mean gene expression levels
with a Benjamini-Hochberg false discovery rate of P <
0.05. The PathDIP database (http://ophid.utoronto.ca/
pathDIP) was used to identify over-represented signaling
pathways using data from significantly upregulated and
downregulated genes through functional enrichment
analysis. Statistical significance was defined at the level
of P < 0.05 and all analyses were carried out using SPSS,
IBM® SPSS® Statistics, version 23, 2015.
Results
Characteristics of study participants
Characteristics of the study subjects are provided in
Table 1. Women with a BRCA1 mutation were signifi-
cantly older than women without a BRCA1 mutation
(43.6 vs. 34.4 years; P = 0.007), more likely to be of
Ashkenazi Jewish descent (32 % vs. 8 %; P = 0.04), to be
parous (77.3 % vs. 33.3 %; P = 0.003), and to have had a
prophylactic mastectomy (41 % vs. 0 %; P <0.001).
BRCA1 mutation carriers were also more likely than
non-carriers to have undergone a prophylactic salpingo-
oophorectomy (59 % vs. 3 %; P < 0.001), and conse-
quently, a greater proportion were postmenopausal
(59 % vs. 11 %; P < 0.001) and had used hormone re-
placement therapy (HRT) (32 % vs. 8 %; P = 0.03). The
two groups were similar in terms of breastfeeding, age at
menarche, oral contraceptive (OC) use, smoking status,
alcohol consumption, and BMI (P ≥ 0.20).
BRCA1 mutation status significantly contributes to lower
overall BRCA1 expression levels
The nCounter Analysis System allows the direct meas-
urement of the number of RNA transcripts of the
BRCA1 gene, herein, expressed as counts. In the univari-
ate analysis, BRCA1 mutation carriers had significantly
lower mean BRCA1 mRNA expression compared to
non-carriers (146.7 counts vs. 175.1 counts; P = 0.002)
(Fig. 1, Table 1 and Additional file 1: Table S1). As
BRCA1 mRNA expression levels had a normal distribu-
tion as determined by the Shapiro-Wilk test of normality,
we employed linear regression modeling to investigate
factors associated with BRCA1 expression (Tables 2 and 3
and Additional file 2: Table S2). We found that mutation
status, parity, breastfeeding, menopause, and oophorec-
tomy were each significantly correlated with lower BRCA1
mRNA levels (P ≤ 0.02) (Table 3). Although not signifi-
cant, age, age at menarche, current OC use and smoking
status were negatively associated with BRCA1 mRNA
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counts while current alcohol consumption and HRT use
were positively associated with BRCA1 mRNA counts.
As BRCA1 mutation status was the most significant con-
tributor to reduced BRCA1 mRNA expression counts in the
univariate analysis, we also evaluated this relationship after
adjusting for parity, breastfeeding, menopause, and oophor-
ectomy. Covariates were selected based on the univariate
analysis showing statistically significant correlations with
BRCA1 mRNA counts (Table 2 and Additional file 2: Table
S2). For the final regression model, parity, breastfeeding,
menopause and mutation status were included in the ana-
lysis. As oophorectomy results in menopause, it was ex-
cluded from the analysis to prevent over-adjustment.
Multivariate modeling demonstrated that carrying a BRCA1
mutation remained the most significant predictor of BRCA1
mRNA levels (Table 3). After adjusting for other important
covariates, women with a BRCA1 mutation had 22.5 lower
counts of BRCA1 mRNA levels compared to non-carriers
(P= 0.04). These data suggest that BRCA1 mutation status
alone predicts BRCA1mRNA expression levels.
BRCA1 mRNA expression levels are mutation specific
Next we characterized BRCA1 mRNA expression by
mutation position and type (Table 4 and Fig. 1). Germ-
line mutations in BRCA1 may be located within any of
the 22 exons of the gene, with the majority of known
pathogenic mutations generating premature termination
codons (PTCs). mRNA transcripts with PTCs are typic-
ally degraded by a mechanism called nonsense-mediated
mRNA decay (NMD) in order to prevent the synthesis
of potentially harmful truncated protein products [44].
The decay of mutant BRCA1 mRNA has been shown to
result in a 1.5 to 5-fold decrease in mRNA abundance;
however, PTCs located very close to the translation initi-
ation codon in exon 2 (185delAG) or in the last exon
(i.e., 5382insC) may escape NMD [44, 45]. Table 4 out-
lines the mutation type and location within the gene and
whether the mutation type results in NMD [28, 44, 46].
There were seven distinct BRCA1 mutations among the
22 study participants with a known BRCA1 mutation.
The mutation type for two of the 22 mutation carriers
was unknown. Fourteen of the 22 mutation carriers
shared one of two specific mutations: (1) 185delAG or
(2) 5382insC, both of which are likely to escape
nonsense-mediated mRNA decay. Three distinct muta-
tions, including, 2190delA, 1293del40, and 3748G > T,
were suggested to undergo NMD and had lower BRCA1
mRNA expression counts compared to mutations that
escape NMD, though not statistically significant (mean
counts of 130.5 vs. 153 counts, respectively, P = 0.15).
Large rearrangement mutations, including deletion exons
1–2 and deletion exons 4–6, had different expression








Age (years), mean (range) 38 (18–62) 34.4 (18–62) 43.6 (27–62) 0.007
Ethnicity, n (%)
Other white 34 (59 %) 20 (56 %) 14 (64 %) 0.04
Ashkenazi Jewish 10 (17 %) 3 (8 %) 7 (32 %)
Hispanic 3 (5 %) 3 (8 %) 0 (0 %)
East Asian 7 (12 %) 6 (17 %) 1 (4 %)
South Asian 4 (7 %) 4 (11 %) 0 (0 %)
Parous, ever, n (%) 29 (50 %) 12 (33.3 %) 17 (77.3 %) 0.003
Breastfeeding, ever, n (%)a 23 (79 %) 10 (83 %) 13 (76 %) 1.00
Age at menarche (years), mean (SD) 12.4 (1.4) 12.2 (1.2) 12.7 (1.7) 0.20
Postmenopausal, n (%) 17 (29 %) 4 (11 %) 13 (59 %) <0.001
Current oral contraceptive use, yes, n (%) 6 (10 %) 4 (11 %) 2 (9 %) 1.00
Current smoking status, yes, n (%) 1 (2 %) 0 (0 %) 1 (5 %) 0.40
Current alcohol consumption, yes, n (%) 51 (88 %) 31 (86 %) 20 (91 %) 0.70
Prophylactic bilateral mastectomy, yes, n (%) 9 (16 %) 0 (0 %) 9 (41 %) <0.001
Prophylactic oophorectomy, yes, n (%) 14 (24 %) 1 (3 %) 13 (59 %) <0.001
Current hormone replacement therapy, yes, n (%) 10 (17 %) 3 (8 %) 7 (32 %) 0.03
BMI, kg/m2 (SD) 24.2 (5) 24.6 (5) 23.5 (4) 0.39
BRCA1 mRNA expression, mean (95 % CI) 164.3 (155, 173.5) 175.1 (163.4, 187) 146.7 (134.2, 159) 0.002
aBreastfeeding among parous women. n number, SD standard deviation, BMI body mass index defined as mass in (kg) divided by height squared in (m2), CI
confidence interval
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levels at 95.56 counts and 157.12 counts, respectively.
Interestingly, participants with mutations that do not
undergo NMD had variable expression levels, suggesting
that additional factors might regulate BRCA1 mRNA
levels (Fig. 1b). For example, 185delAG BRCA1 mutation
carriers had expression levels ranging between 109.9 and
153.3 counts. Similarly, 5382insC BRCA1 mutation car-
riers had expression levels ranging between 118.4 and
195.9 counts. Overall, the data suggest BRCA1 basal
mRNA expression levels may be mutation specific.
Recently, Rebbeck et al. [28] reported that mutations in
the 5′ and 3′ regions of BRCA1 were associated with an
increased risk of breast cancer, while mutations in exon
11 were associated with an increased risk of ovarian vs.
breast cancer. To determine if these specific mutation
clusters were associated with differential BRCA1 mRNA
expression in our cohort, mutations were pooled into
three groups: group 1 containing mutations in exons
1–10; group 2 containing mutations in exon 11; and group
3 containing mutations in exons 12–22 (Fig. 2a, b) [28].
Mutations within exon 11 had lower mRNA expression
levels (122.1 counts) compared to mutations within the 5′
(138.9 counts) and 3′ (168.6 counts) regions of the
BRCA1 gene (P = 0.003) (Fig. 2a, b).
BRCA1 mutation carriers have similar gene expression
profiles
To further characterize the gene expression profiles of
freshly isolated blood leukocytes from women with and
without a BRCA1 mutation, unsupervised clustering,
using a Pearson-centered correlation metric with
centroid linkage rules of the normalized genes, was per-
formed across all the samples. Interestingly, the samples
tended to cluster based on BRCA1 mutation status
(Fig. 3). Out of 236 genes included in the nCounter® GX
Human Cancer Reference Kit, we identified eight genes
to be significantly downregulated in carriers (Table 5),
including BRCA1, CSK, NRAS, PCTK1, TGFBR2,
TNFSF10, TOP1, and XPC. Nine genes were significantly
upregulated in carriers, including BCR, CLTC, FLT3, IL8,
Fig. 1 BRCA1 mRNA expression levels are mutation specific. a Box plot analysis of mean BRCA1 mRNA expression counts in 22 BRCA1mutation carriers
compared to 36 non-carriers, (146.7 vs. 175.1, P= 0.002, respectively). b Distribution of BRCA1mRNA expression across BRCA1mutation carriers compared
to non-carriers (i.e., control). Control denotes the mean BRCA1 mRNA expression levels across 36 participants with wild-type BRCA1 gene status. Error bars
represent the standard deviation of mean BRCA1 mRNA expression counts. UI mutation is unidentified
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LMO2, PTPN11, REL, TGFB1 and TNFRSF10B at a
Benjamini-Hochberg false discovery rate <0.05 using the
t test (Table 6). PathDIP (http://ophid.utoronto.ca/
pathDIP) was used for pathway enrichment analysis
and identified pathway associations for 94 % of genes.
PathDIP analysis showed significant enrichment for
cancer pathways (especially colorectal and pancreatic
cancers), Toll-like receptor signaling, RAS signaling, and
numerous other pathways (Additional file 3: Table S3)
(P < 0.0000001). Upregulated genes were most enriched
for integrins in angiogenesis, advanced glycation end
products and receptor AGE-RAGE in inflammation, and
apoptosis pathways (P < 0.0000001). Downregulated genes
were most enriched for EGF, RAS, and DNA repair path-
ways, and for hearing and vision proteins (P < 0.0001).
Discussion
The goal of the current study was to evaluate whether
BRCA1 mRNA expression levels are reduced in the leu-
kocytes of women with a BRCA1 mutation. We found
that carrying a BRCA1 mutation was the most signifi-
cant predictor of BRCA1 mRNA levels. BRCA1 mRNA
levels were significantly lower in mutation carriers
compared to non-carriers (146.7 counts vs. 175.1 counts;
P = 0.002). Furthermore, mutations within exon 11 were
associated with lower mRNA expression levels compared
to mutations within the 5′ and 3′ regions of the BRCA1
gene (122 counts vs. 138 and 167 counts, respectively;
P = 0.003). In addition, 17 other genes in a panel of 236
genes, some of which have been previously shown to be
involved in breast and ovarian carcinogenesis, were also
differentially expressed between the two groups of women.
Overall, these findings support the concept of BRCA1
haploinsufficiency, whereby a dosage-dependent effect of
the BRCA1 gene is associated with molecular alterations
at the transcriptional level. Reduced BRCA1 mRNA expres-
sion levels were previously reported in BRCA1-associated
cancer [38]. To our knowledge, this is the first study to
identify lower BRCA1 expression in leukocytes from
healthy, unaffected BRCA1 mutation carriers. Whether
lower BRCA1 transcript levels translate to changes in pro-
tein levels or to carcinogenesis remains to be determined.
Emerging evidence from epidemiologic studies, from
human tissue culture model systems and from murine
studies supports a continuum of tumor suppression
where BRCA1 expression levels might be tightly corre-
lated with function [9]. Recently, Pathania et al. reported
that human breast epithelial and skin fibroblast cells
from BRCA1 mutation carriers had lower BRCA1 pro-
tein levels that were associated with haploinsufficiency
for stalled replication fork repair/replication stress and
conditional haploinsufficiency for HR-DSB [22]. Under
concurrent forms of stress, such as UV and IR that re-
quire BRCA1 mediated HR-DSB, the pool of available
BRCA1 is not sufficient to repair all the damage, thereby
leading to the accumulation of small genomic aberra-
tions. When these aberrations reach a threshold above
which the damage is irreparable, genomic instability en-
sues and drives malignant transformation [8]. Conse-
quently, identifying BRCA1 mutations that result in low
basal expression levels might help stratify cancer risk.
More recently, Sedic et al. showed that BRCA1 mutation
carriers exhibit cell-type-specific haploinsufficiency for
genomic instability, whereby human mammary epithelial
cells from BRCA1 mutation carriers had shorter telo-
meres that contributed to premature senescence com-
pared to non-carriers [23]. If these in vitro findings
translate to mammary epithelial cells having a reduced
life span in vivo, then additional genomic alterations are
required to bypass premature senescence. Whether
Table 3 The mutation status is the most significant contributor
to reduced BRCA1 mRNA levels after adjusting for parity,
breastfeeding, and menopause
Model B Coefficient (95 % CI) P value
Constant 179 (128.4, 207.5) <0.001
Mutation status −22.5 (−43.3, −1.7) 0.04
Pregnancy 3.5 (−28, 35) 0.80
Breastfeeding −9.3 (−24, 5.6) 0.20
Menopause −3.5 (−28, 20) 0.70
The model of best-fit incorporated factors significantly contributing to reduced
BRCA1 expression levels by linear regression. Covariates were selected based
on univariate analyses showing statistically significant correlations with BRCA1
mRNA levels. The mutation status remains the most significant contributor to
lower BRCA1 mRNA levels after adjusting for parity, breastfeeding, and
menopause (P = 0.04). P value denotes the contribution of each covariate to
the linear regression model
Table 2 Correlation between reproductive or lifestyle factors




Age −0.63 (−1.3, 0.07) 0.08
Parity (ever) −22.3 (−40, −4.8) 0.01
Breastfeeding (ever) −12 (−22, −3) 0.009
Age at menarche −3.7 (−10.2, 2.8) 0.30
Menopause −23.3 (−43, −4) 0.02
Current oral contraceptive use −2.5 (−33, 30) 0.90
Current smoking status −9.3 (−45, 26) 0.60
Current alcohol consumption 0.115 (−28, 28) 1.00
Mastectomy −15.3 (−41, 10) 0.23
Oophorectomy −24 (−45, −3.4) 0.02
Current hormone replacement therapy use 0.5 (−11.8, 12.8) 0.93
Body mass index 0.445 (−1.5, 2.3) 0.65
Mutation status −28.5 (−46, −11) 0.002
Data are provided as linear regression coefficient, Unstandardized B coefficient
and 95 % confidence intervals. P value < 0.05 denotes statistical significance
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BRCA1 expression levels can predict cells that are at in-
creased risk of escaping senescence remains to be
determined.
A number of epidemiologic reports suggest tumor type
predisposition differs according to the position of the
BRCA1 mutation [27–29]. In an analysis of 60 families
with a history of breast or ovarian cancer, Gayther et al.
showed that BRCA1 mutations mapping up to and includ-
ing exon 12 were linked to a higher ratio of ovarian to
breast cancers compared to mutations mapping to the C-
terminal portion of the BRCA1 gene [29]. Moreover, using
genotype-phenotype correlations in 356 families with
pathogenic BRCA1 mutations, Thompson et al. showed
that the ovarian to breast cancer ratio was higher with
mutations in the central region of the BRCA1 gene (nucle-
otides 2401-4190; predominantly within exon 11) [27]. In
a systemic analysis of 19,581 carriers of BRCA1 mutations,
Rebbeck et al. identified that mutation clusters mapped to
the 5′ (BCCR1, c.179 to c.505) and 3′ (BCCR2, c.4328 to
c.4945 and BCCR2′, c.5261 to c.5563) regions of BRCA1
were associated with increased breast cancer risk, while
mutations mapped to exon 11 were associated with in-
creased ovarian cancer risk [28].
In the current study, we showed that mutations within
exon 11 had the lowest mRNA expression levels com-
pared to mutations within the 5′ and 3′ regions of the
BRCA1 gene, with nonsense-mediated decay being the
most likely mechanism mediating mutation-dependent
reduced transcript level readout. It remains to be deter-
mined how mutation-dependent modulation of BRCA1
expression levels affects the different functions of
BRCA1, i.e., which mutations confer a dominant nega-
tive role compared to mutations that retain partial wild-
type BRCA1 function, whether functions involving do-
mains within exon 11 are more relevant to ovarian epi-
thelium function and whether those within domains of
the 3′ and 5′ regions more relevant to breast epithelium
functioning [29].
Conditional Brca1 mouse models have also provided
insight into functional correlates of different BRCA1
mutations. Mouse strains carrying loss of Brca1 and het-
erozygous p53 mutations are conditionally targeted to
mammary epithelial cells using Cre-lox system. Shakya
et al. showed that introduction of a brca1 mutation
I26A, which impairs E3 ubiquitin ligase activity but
maintains the interaction with Bard1, does not lead to
Table 4 Overview of BRCA1 mutation type and association with nonsense-mediated decay
Study ID Age BRCA1 mutation Mutation type Exon aNonsense-mediated decay (NMD)
1 33 Deletion Exon 1-2 FS 1–2 Unknown
2 54 185delAG FS 2 -
3 31 185delAG FS 2 -
4 27 185delAG FS 2 -
5 36 185delAG FS 2 -
6 58 185delAG FS 2 -
7 58 185delAG FS 2 -
8 44 185delAG FS 2 -
9 50 185delAG FS 2 -
10 35 Deletion Exon 4-6 FS 4–6 Unknown
11 54 2190delA FS 11 +
12 60 1293del40 FS 11 +
13 33 3748G > T NS 10 +
14 51 1293del40 FS 11 +
15 33 5382insC FS 20 -
16 38 5382insC FS 20 -
17 62 5382insC FS 20 -
18 52 5382insC FS 20 -
19 35 5382insC FS 20 -
20 38 5382insC FS 20 -
21 41 UI
22 37 UI
aNonsense-mediated decay (NMD) status was based on experimental investigations by Liu et al. and Perrin-Vidoz et al. [44–46] and other reports [19–28]. UI mutation is
unidentified, FS frameshift mutation, NS Nonsense mutation, NMD (+) nonsense-mediated decay is present, NMD (-) nonsense-mediated decay is absent, NMD (Unknown)
functional contribution of NMD to mRNA expression levels in these mutations remains to be explored
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tumor formation; whereas mutation of the BRCT do-
main (S1598F) that disrupts phosphoprotein binding re-
sulted in a high rate of tumor formation [26]. Drost et
al. demonstrated that the Brca1 (C61G) missense muta-
tion, which impairs BRCA1/BARD1 heterodimerization
and ubiquitin ligase activity, resulted in mammary tu-
mors that were resistant to cisplatin and PARP inhibitors
compared to Brca1 null mice [25]. Overall, these studies
suggest that all BRCA1 mutations are not equivalent in
their tumorigenic potential, and consequently, cancer
risk assessment might be mutation specific.
The present study also highlights BRCA1 mutation status
as a significant classifier based on global gene expression
profiling. Pathway enrichment analysis revealed gene expres-
sion alterations that are tissue specific, including genes that
mediate acute/chronic leukemia. Interestingly, enrichment
of genes involved in Toll-like receptor signaling and IL-2-
mediated signaling in BRCA1 mutation carriers, suggests
that changes in the immune microenvironment might occur
early on in heterozygous cells and may be useful for targeted
prevention strategies. Furthermore, downregulated genes
were enriched in DNA damage response pathways, thereby
supporting the growing evidence for BRCA1 haploinsuffi-
ciency in DNA damage repair as a potential early tumor
predisposing event.
Strengths of the current study include the use of RNA
from blood leukocytes that was stabilized within 30 minutes
of collection, resulting in high quality RNA (mean RNA in-
tegrity number, RIN = 8.7), and the use of the NanoString
nCounter Analysis System to quantify mRNA expression,
which helps to achieve high validity, reproducibility, and
sensitivity [42]. The primary limitation of our study is that
the BRCA1 expression analysis was not allele-specific, i.e.,
the lower mRNA counts in leukocytes of BRCA1 mutation
carriers extend beyond nonsense-mediated decay of the
mutant allele to include mechanisms, such as microRNA-
mediated regulation of expression levels of wild-type or
mutant-type alleles, and altered expression levels of regula-
tors of BRCA1 mRNA levels in BRCA1 mutation carriers
vs. non-carriers. Future studies using RNA sequencing,
which can discriminate between levels of the wild-type and
mutant allele are warranted. Other limitations include the
relatively small sample size that allowed for the evaluation
of a narrow spectrum of BRCA1mutations and their effects
on BRCA1 gene expression levels.
Collectively, these data support the concept of BRCA1
haploinsufficiency, whereby BRCA1 heterozygous cells
have lower BRCA1 mRNA expression levels. Since the
evaluation of BRCA1 protein levels as a surrogate
marker of BRCA1 haploinsufficiency posits a challenge,
especially in freshly isolated leukocytes, our study high-
lights the role of using BRCA1 mRNA levels as an indi-
cator of prospective BRCA1 functional levels. Factors
that increase BRCA1 levels to a normal level might
Fig. 2 Stratification of mean BRCA1 mRNA expression counts by BRCA1 mutation clusters associated with differential risk for breast and/or ovarian
cancers. a Box plot distribution of mean BRCA1 mRNA counts by location of mutation compared to non-carriers. ANOVA analysis of variance.
b 1Mutations were sub-classified into three clusters: mutations in the 5′ terminal (Exons 1-10) and 3′ terminal (Exons 12-22) of exon 11 include
three previously identified breast cancer cluster regions (BCCRs) proposed to have increased risk for breast vs. ovarian cancer. Mutations within
exon 11 were shown to have increased risk for ovarian vs. breast cancer [28]
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restore BRCA1 function. We recently demonstrated that
daily oral supplementation with 3,3′-diindolylmethane
(i.e., DIM) for 4–6 weeks resulted in a significant 34 %
increase in BRCA1 mRNA expression in leukocytes from
women with a BRCA1 mutation [47]. Elsewhere, seden-
tary behavior was associated with significantly lower
BRCA1 mRNA levels in women with and without a mu-
tation [48]. These studies provide important mechanistic
insight into how a lifestyle factor may mediate cancer
risk in this high-risk population.
Conclusions
In summary, our findings suggest that BRCA1 mutation
status is a significant predictor of lower BRCA1 mRNA
levels in peripheral blood leukocytes. In turn, this may
provide a feasible tool whereby modulation of BRCA1
levels through different interventions can be monitored
in the clinical setting or can stratify risk. The possibility
Table 5 A summary of genes significantly downregulated in
samples of BRCA1 mutation carriers compared to non-carriers
(Benjamini-Hochberg false discovery rate < 0.05 using the t-test)
Gene Gene name P value
CSK c-Src tyrosine kinase 0.000
NRAS Neuroblastoma RAS viral (v-ras) oncogene
homolog
0.000
TGFBR2 Transforming growth factor, beta receptor II 0.001
XPC Xeroderma pigmentosum, complementation
group C
0.001
BRCA1 Breast cancer 1, early onset 0.002
PCTK1/CDK16 Cyclin-dependent kinase 16 0.008
TOP1 Topoisomerase (DNA) I 0.008
TNFSF10 Tumor necrosis factor (ligand) superfamily,
member 10
0.009
Fig. 3 Comparison of gene expression profiles of BRCA1 mutation carriers
(n = 22) and non-carriers (n = 36). a Heat map showing unsupervised
hierarchical clustering of 236 genes from the Nanostring Cancer Reference
gene panel across BRCA1 mutation carriers and non-carriers. BRCA1 Mut:
BRCA1 mutation carrier status and type; BRCA1 WT: BRCA1 wild-type gene
status. b Unsupervised hierarchal clustering of gene expression profiles of
freshly isolated blood leukocytes from BRCA1 mutation carriers and
non-carriers, showing samples cluster by BRCA1 mutation status: 9/22
BRCA1 mutation carriers share similar gene expression profiles and cluster
more closely together. Heat map shows the top differentially expressed
genes and corresponding gene pathway enrichment analysis; green shows
relatively under expressed genes and pathways, respectively; red shows
relatively over-expressed genes and pathways, respectively
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of mitigating the effect of an inherited deleterious
BRCA1 mutation by increasing the physiologic expres-
sion of the gene and normalizing protein levels repre-
sents a clinically important paradigm shift in the
prevention strategies available to these high-risk women.
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